Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail

v3.5.0.2
Condensed Consolidated Financial Statements Detail
9 Months Ended
Sep. 30, 2016
Condensed Consolidated Financial Statements Detail [Abstract]  
Condensed Consolidated Financial Statements Detail

3. Condensed Consolidated Financial Statements Detail

Cash and Cash Equivalents

As of September 30, 2016, cash and cash equivalents consisted of demand deposits of $4.1 million and money market funds of $16.5 million with maturities of less than 90 days at the date of purchase. As of December 31, 2015, cash and cash equivalents consisted of demand deposits of $23.2 million and money market funds of $42.6 million with maturities of less than 90 days at the date of purchase.

Marketable Securities

As of December 31, 2015, marketable securities of $0.5 million consisted of an investment in the common stock of a public entity. In August 2016, the Company sold all of its marketable securities and recognized a gain of $0.1 million in the Company’s condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2016. Accordingly, as of September 30, 2016, the Company did not hold any marketable securities.


Accrued and Other Liabilities  

Accrued and other liabilities consisted of the following (in thousands):

 

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

Accrued payroll and other benefits

 

$

1,682

 

 

$

2,156

 

Deferred rent

 

 

782

 

 

 

608

 

Accrued clinical trial costs

 

 

669

 

 

 

406

 

Accrued incentive compensation

 

 

569

 

 

 

2,609

 

Accrued legal and accounting fees

 

 

389

 

 

 

517

 

Other

 

 

723

 

 

 

729

 

Total

 

$

4,814

 

 

$

7,025

 

 

Net Loss Per Share of Common Stock

Potentially dilutive securities are excluded from the calculation of diluted net loss per share of common stock if their inclusion is anti-dilutive.

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

 

 

 

Three  Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

Common stock options and RSUs

 

 

558

 

 

 

548

 

 

 

549

 

 

 

481

 

Warrants for common stock

 

 

917

 

 

 

908

 

 

 

915

 

 

 

908

 

Total

 

 

1,475

 

 

 

1,456

 

 

 

1,464

 

 

 

1,389